FIG. 1



SAHA Patient: IV vs ORAL (200 mg/dose)
Patient #
1-OS-200
Week 1
Week 2
IV
ORAL
-
+
Marker
Pre
Post
Pre
Post-2hrs
Post-4hrs
α-AcH4
Coomassie blue

FIG. 2



Protocol 01-021 (ORAL SAHA) ARM A: SOLID TUMOR PATIENTS Cohort I (200 mg/dose)
IV
ORAL
Pre
Post
Pre
2hrs
4hrs
Patient #
1-OS-200 (8-21-01)
1 hr
α-AcH4
Coomassie stain
2-OS-200 (10-16-01)
α-AcH3
Coomassie stain

FIG. 3



SAHA Patients: ORAL /Cohort I (200 mg/dose)
IV
Day 1 ORAL
Pre
Post
Pre
2hrs
4hrs
1-OS-200
(8-21-01)
α-AcH4
Coomassie stain
Day 21 ORAL
1 hr
4hrs
Pre
1hr
4hrs
2-OS-200
(11-14-01)
α-AcH3
Coomassie stain
0.5 hrs
2.5 hrs
3-OS-200
(10-16-01)
α-AcH3
Coomassie stain
0.5 hrs
4hrs
4-OS-200
(11-6-01)
α-AcH3
Coomassie stain
Day 21 ORAL
1 hr
4 hrs
Pre
1hr
4hrs
5-OS-200
(12-4-01)
α-AcH3
Coomassie Blue

FIG. 4



Protocol 01-021 (ORAL SAHA)
ARM A: SOLID TUMOR PATIENTS
Cohort I (200 mg/dose)
IV
Pre
Post
Day 8 ORAL
Pre
1 hr
4 hrs
Day 21 ORAL
Pre
1 hr
4 hrs
α-AcH3
Coomassie stain
6-OS-200
(12-13-01)

FIG. 5




Protocol 01-021 (ORAL SAHA)
ARM A: SOLID TUMOR PATIENTS
Cohort IIa (400 mg/dose)
7-OS-400
8-OS-400
9-OS-400
IV
ORAL
Markers
-
+
Pre
Post
15 min
2 hr
6 hr
0 hr
12/19/01
12/27/01
α-AcH3
Coomassie stain

FIG. 6


SAHA Patients: ORAL/Cohort II (400 mg/dose)
9-OS-400
10-OS-400
IV
ORAL
IV
ORAL
Markers
+
-
Pre
2 hrs
Pre
2 hrs
6 hrs
Pre
2 hrs
8 hrs
α-AcH3
Coomassie stain




FIG. 7

Protocol 01-021
(ORAL SAHA)
ARM A: SOLID
TUMOR PATIENTS
Cohort IIa (400 mg/dose)

FIG. 8



SAHA Patients: ORAL/Cohort II (400 mg/dose)
11-OS-400
IV
ORAL
12-OS-400
IV
ORAL
Markers
+
-
Pre
2 hrs
Pre
2 hrs
10 hrs
Pre
2 hrs
Pre
2 hrs
10 hrs
α-AcH3
Coomassie stain
01/24/02
12-OS-400
IV
DAY 1 ORAL
DAY 21 ORAL
Markers
+
-
Pre
2 hrs
Pre
2 hrs
10 hrs
Pre
2 hrs
9.25 hrs
α-AcH3
Coomassie stain
02/15/02

FIG. 9A

Oral 200 mg vs. 400 mg (Fasting)
Oral dose on Cycle 1 Day 8




FIG. 9B

Oral 200 mg vs. 400 mg (no-fasting)
Oral Dose on Cycle 1 Day 9




FIG. 9C

IV 200 mg vs. 400 mg
IV Dose on Cycle 1 Day 1




FIG. 10

Apparent Half-life of the Oral Dose
Half-life




FIG. 11

AUC of the Oral
Dose AUC_last





FIG. 12


Bioavailability after 200 and 400 mg by Day
1.00
0.75
0.50
0.25
0.00
Day 8
Fasting
Day 9
w/ Food
Day 22
Fasting
200 mg
400 mg
F ~ 48%





FIG. 13




A B

FIG. 14




B



A

FIG. 15



A B

FIG. 16




FIG. 17